Lower Prolactin Levels in Patients Treated With Aripiprazole Regardless of Antipsychotic Monopharmacy or Polypharmacy.
Adult
Aged
Antipsychotic Agents
/ adverse effects
Aripiprazole
/ adverse effects
Cross-Sectional Studies
Down-Regulation
Drug Therapy, Combination
Female
Health Care Surveys
Humans
Inpatients
Male
Middle Aged
Polypharmacy
Prolactin
/ blood
Schizophrenia
/ blood
Schizophrenic Psychology
Treatment Outcome
Journal
Journal of clinical psychopharmacology
ISSN: 1533-712X
Titre abrégé: J Clin Psychopharmacol
Pays: United States
ID NLM: 8109496
Informations de publication
Date de publication:
Historique:
pubmed:
14
12
2019
medline:
2
6
2020
entrez:
14
12
2019
Statut:
ppublish
Résumé
Hyperprolactinemia is a troublesome adverse effect of antipsychotics. Aripiprazole (ARP), which is one of second-generation antipsychotics, has been reported to lower serum prolactin (PRL) levels. However, few studies have compared the effect of ARP on plasma PRL levels between monopharmacy and polypharmacy with antipsychotics. We conducted a large-scale investigation of the physical risk for inpatients with schizophrenia using a questionnaire covering demographic data, the number, dose and type of antipsychotics, and serum PRL levels. Sufficient data to conduct an assessment of the effect on PRL levels between antipsychotic monopharmacy and polypharmacy were obtained from 316 of the inpatients. Serum PRL levels in ARP combination group were lower than non-ARP combination group, regardless of antipsychotic monopharmacy or polypharmacy. The present study suggests that ARP lowers serum PRL levels regardless of monopharamacy or polypharmacy with antipsychotics.
Sections du résumé
BACKGROUND
BACKGROUND
Hyperprolactinemia is a troublesome adverse effect of antipsychotics. Aripiprazole (ARP), which is one of second-generation antipsychotics, has been reported to lower serum prolactin (PRL) levels. However, few studies have compared the effect of ARP on plasma PRL levels between monopharmacy and polypharmacy with antipsychotics.
METHODS
METHODS
We conducted a large-scale investigation of the physical risk for inpatients with schizophrenia using a questionnaire covering demographic data, the number, dose and type of antipsychotics, and serum PRL levels.
RESULTS
RESULTS
Sufficient data to conduct an assessment of the effect on PRL levels between antipsychotic monopharmacy and polypharmacy were obtained from 316 of the inpatients. Serum PRL levels in ARP combination group were lower than non-ARP combination group, regardless of antipsychotic monopharmacy or polypharmacy.
CONCLUSIONS
CONCLUSIONS
The present study suggests that ARP lowers serum PRL levels regardless of monopharamacy or polypharmacy with antipsychotics.
Identifiants
pubmed: 31834097
doi: 10.1097/JCP.0000000000001158
pii: 00004714-202001000-00004
doi:
Substances chimiques
Antipsychotic Agents
0
Aripiprazole
82VFR53I78
Prolactin
9002-62-4
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
14-17Références
Kucka M, Tomić M, Bjelobaba I, et al. Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs. Sci Rep. 2015;5:8902.
Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol. 2006;21:529–532.
Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry. 2005;66:761–767.
Rosenberg KP, Bleiberg KL, Koscis J, et al. A survey of sexual side-effects among severely mentally ill patients taking psychotropic medications: impact on compliance. J Sex Marital Ther. 2003;29:289–296.
Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multipletreatments meta-analysis. Lancet. 2013;382:951–962.
Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry. 2011;168:947–956.
Lee MS, Song HC, An H, et al. Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, singleblind, placebo-controlled, multicenter study. Psychiatry Clin Neurosci. 2010;64:19–27.
Urban JD, Vargas GA, von Zastrow M, et al. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology. 2007;32:67–77.
Natesan S, Reckless GE, Nobrega JN, et al. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology. 2006;31:1854–1863.
Raghuthaman G, Venkateswaran R, Krishnadas R. Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial. BJPsych Open. 2015;14:172–177.
Kane JM, Correll CU, Goff DC, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009;70:1348–1357.
Yasui-Furukori N, Furukori H, Sugawara N, et al. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol. 2010;30:596–599.
Correll CU. Antipsychotic polypharmacy, part 1: shotgun approach or targeted cotreatment. J Clin Psychiatry. 2008;69:674–675.
Sim K, Su A, Leong JY, et al. High dose antipsychotic use in schizophrenia: findings of the REAP (research on East Asia psychotropic prescriptions) study. Pharmacopsychiatry. 2004;37:175–179.
Lu ML, Shen WW, Chen CH. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1978–1981.
Byerly MJ, Marcus RN, Tran QV, et al. Effects of aripiprazole on prolactinlevelsinsubjectswithschizophreniaduringcross-titrationwith risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res. 2009;107:218–222.
Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonistat human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381–389.
Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is apotent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441:137–140.
Ministry of Health and Welfare. Patient Survey 1996. Statistics and Information Department, Minister's Secretariat, Ministry of Health and Welfare, Tokyo, 1999 (in Japanese).
Carter MI, Hinton PS. Physical activity and bone health. Mo Med. 2014;111:59–64.
Galling B, Roldán A, Rietschel L, et al. Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opin Drug Saf. 2016;15:591–612.
Srisurapanont M, Suttajit S, Maneeton N, et al. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. J Psychiatr Res. 2015;62:38–47.
Tiihonen J, Taipale H, Mehtälä J, et al. Association of Antipsychotic Polypharmacy vs Monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiat. 2019;76:499–507.